Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

  1. Our Science
FILTER
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab, or secukinumab: Results from phase III/IIIb trials.

Kokolakis Georgios, Warren B. Richard, Strober Bruce et al.  February 22, 2023
phase 2

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE 

Philip J Mease, Akihiko Asahina, Gladman D. Dafna et al.  February 01, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde, Deodhar A. Atul, Xenofon Baraliakos et al.  January 17, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Iain B McInnes, Akihiko Asahina, Laura C Coates et al.  January 07, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Landewé B.M. Robert, Iain B McInnes et al.  January 07, 2023
phase 2

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

Xenofon Baraliakos, Deodhar Atul, Dougados Maxime et al.  November 22, 2022
phase 2

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study 

Laura C Coates, Iain B McInnes, Joseph F Merola et al.  November 18, 2022
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis.

Armstrong April, K. Fahrbach, Leonardi Craig et al.  July 07, 2022
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled results from phase 2 and phase 3 randomized clinical trials.

Gordon B. Kenneth, Langley G. Richard, Warren B. Richard et al.  July 01, 2022
phase 4

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17

Armstrong W. April, Blauvelt Andrew, Mrowietz Ulrich et al.  February 15, 2022